Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma [A19276]. It is transported across the membranes including the blood-brain barrier into various tissues where it plays an essential role in the DNA synthesis, cysteine cycle and regulation of homocysteine, where it methylates homocysteine and forms methionine and tetrahydrofolate (THF). Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773]. It is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement [A19276]. Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms.
Levomefolate Calcium, Acetylcysteine, Mecobalamin and Algal
Virt-PN DHA
Tendera-OB
Tri-Vi-Flor
Obstetrix DHA Combo Pack
Finazol
Niferex
Poly-Vi-Flor with Iron
Tydemy
L-Methylfolate Calcium
Levomefolate Calcium, Pyridoxal 5-phosphate, Methylcobalamin and Schizochytrium DHA Oil
Prenate Pixie
WellFola
Multi-Vit-Flor
Drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
EnBrace HR
Vitafol Fe Plus
Denovo
Hemax
Davimet with Iron
Quflora FE
Virt-Pn
Enl
Multivitamin with Fluoride
Sulfzix
Select OB
Safyral
NuFera
PaxLyte
Puralor
Yaz Plus
L-Methyl MC
Medi-10
EnLyte
Biopar delta-FORTE
FloraFol
LorMate
Levomefolate Calcium Acetylcysteine and Mecobalamin Algal
PNV Tabs 20-1
Floriva
Chromagen
Rajani
Tricare Prenatal Quick Dissolve
PramLyte
BumP DHA
Florravite
Tricare Prenatal DHA One With Folate
Quflora Pediatric Drops
L-Methyl-MC-NAC
Select-OB Plus DHA Prenatal Supplement Plus DHA
Rulavite DHA
Poly-Vi-Flor
Indication
For the treatment and prevention of folate deficiency and for use as an antidote against folic acid antagonists. Contained in oral contraceptives to reduce the risk of neural tube defects arising from folic acid deficiency for pregnant women who conceived during use or shortly after the discontinuation of the product. Being studied for use as a treatment for cardiovascular diseases [A19273] and adjunct therapy for patients undergoing antidepressant pharmacotherapy [A19271, A19272].
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682